AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05729568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Injection
Description: Administered subcutaneously
Study NCT05729568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy
Description: Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.
Study NCT05208164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfunlness Meditation
Description: Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
Study NCT06179498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner Navigation Intervention
Description: A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
Study NCT04888520 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Adhesive elastic bandage
Description: The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist.
Study NCT04888520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive elastic bandage
Description: The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist.
Study NCT05928091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call to an expert team
Description: Patients will be treated as the expert said when the investigator called him
Study NCT04962789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transvaginal ultrasound on the uterus
Description: Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer
Study NCT05373524 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological analysis
Description: Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
Study NCT05373524 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological analysis
Description: Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
Study NCT05511623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
Study NCT05511623 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
Study NCT05440266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Study Intervention: 25 ms half-sine wave stimulation
Description: Part I: Threshold detection and Flare response: 6 pulses of 25 ms half-sine are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 25 ms half-sine is administered continuously.
Study NCT05440266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention: 500 µs rectangular shaped stimulation
Description: Part I: Threshold detection and Flare response: 6 pulses of 500 µs rectangular shaped stimulation are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 500 µs rectangular shaped stimulation is administered continuously.
Study NCT06603922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological treatment (P-MCT)
Description: Personalization will be performed according to the results obtained from the platform. Both the classic MCT and personalized MCT will be the same with regard to specific modules that are offered to patients. However, the personalized MCT will have personalized homeworks that target specific factors, in which patients have deficits. For instance, patients with deficits in self-esteem (based on the results from the platform) will be provided with homework addressing this aspect. We identified five domains that will be personalized: 1. self-esteem; 2. cognitive insight; 3. delusions; 4. positive symptoms; 5. completion.
Study NCT06603922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological treatment (MCT)
Description: Metacognitive training is a cognitive approach to the treatment of positive symptoms in psychosis.~Metacognitive training consists of ten modules referring to common cognitive issues and biases in solving problems in schizophrenia. The topics of MCT include the following: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 \& 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5), mood (module 8), self-esteem (9) and stigma (10).~Each session lasts 45-60 min and follows a protocol defined in the 'Metacognitive Training for Psychosis (MCT)' manual.~The MCT for Schizophrenia programme will be applied to the group (6-12 persons) applied by therapists in each center. The training format (online or in-person) as well as the frequency (1 or 2 times per week) will vary depending on the center.
Study NCT05317988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information
Study NCT05317988 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
Study NCT05938855 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electrical stimulation and biofeedback with the medical device Phenix Liberty
Description: The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.~The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 10 sessions between 10 and 12 weeks~* 1 end visit, within the week after the 10th session
Study NCT05638750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Intervention
Description: 12-week treatment intervention \& home exercised, then 12-week non-intervention period, follow-up visit at end of non-intervention period.
Study NCT06654336 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Recurrence-directed therapy (RDT)
Description: RDT options include radiotherapy or surgical resection.
Study NCT06654336 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Recurrence-directed therapy (RDT)
Description: RDT options include radiotherapy or surgical resection.
Study NCT06654336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELIGARD 22.5mg
Description: ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
Study NCT04975256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor
Study NCT04975256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1701963
Description: SOS1 Inhibitor
Study NCT06044922 — intervention group
Intervention type: DEVICE
Intervention: 24-hour Holter monitoring
Description: Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
Study NCT04683731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision aid without personalized message
Description: The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
Study NCT04683731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid without personalized message
Description: The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
Study NCT04683731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid with personalized message
Description: The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
Study NCT04683731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider notification without personalized message
Description: Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
Study NCT04683731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider notification without personalized message
Description: Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
Study NCT04683731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider notification with personalized message
Description: Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
Study NCT06289673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
Study NCT06289673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenously (IV) for 1 dose on Day 1 or 2
Study NCT06289673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
Study NCT06289673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Description: Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
Study NCT06289673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT as part of Intrathecal triple therapy.
Study NCT06289673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT as part of Intrathecal triple therapy.
Study NCT06602622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Integrase inhibitor
Description: Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine 300 mg (DTG/ABC/3TC); 3) DTG 50mg+TDF 300mg/FTC 200mg (DTG+TDF/FTC) Each will be prescribed one tablet every day during 48 weeks
Study NCT06602622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine + tenofovir DF + lamivudine
Description: Individuals who meet the selection criteria will be randomized to maintain their same regimen with second-generation integrase inhibitors or switch to DOR/TDF/3TC 100/ 300/300 mg It will be prescribed one tablet every day during 48 weeks
Study NCT06593548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib (AK112)
Description: Participants will receive Ivosidenib in combination with CapeOX chemotherapy and radiotherapy. Participants will first receive Ivosidenib in combination with CapeOX during the first cycle, followed by radiotherapy starting 2 weeks after medication. Depending on the dose limits of normal tissue radiation, Stereotactic Ablative Radiotherapy (SABR), large fraction radiotherapy, or high-dose combined with low-dose radiotherapy will be administered to primary and metastatic lesions. One week after completing radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment. If primary and metastatic lesions are too extensive for initial radiotherapy, participants will continue to receive Ivosidenib in combination with CapeOX systemic treatment until the lesions shrink, at which point radiotherapy may be considered.。
Study NCT06604559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discharge using Apollo application
Description: Discharge using Apollo application
Study NCT06604559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular discharge
Description: Discharge with the regular process
Study NCT05929300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga program includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-surgery yoga. The yoga program includes basic yoga poses and breathing exercises.
Study NCT05929300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it.
Study NCT05929300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This consists of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it.
Study NCT05572684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC410
Description: NC410 will be given intravenously (IV) every 2 weeks
Study NCT05572684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 400mg will be given IV every 6 weeks.
Study NCT05232253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cystoelastometer - Urodynamics Testing
Description: The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
Study NCT05700201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle / Healthy Behavior Intervention
Description: 12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
Study NCT05700201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: Standard care (psychotherapy)
Study NCT05069896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab Prefilled Syringe
Description: Administered SC by prefilled syringe
Study NCT05069896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab Autoinjector
Description: Administered SC by autoinjector
Study NCT05196672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality and eye mask
Description: Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
Study NCT05187156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation and Social Engagement
Description: brief, PCMHI-based psychotherapy using behavioral activation principles and focused attention on enhancement of social support
Study NCT05187156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: treatment as usual in PCMHI includes participation in any other skills-based groups or brief individual psychotherapy and medication management offered in PCMHI
Study NCT06589908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAX glasses
Description: Glasses which are a solution of audiovisual sedation by positiv distraction for hospital medical use
Study NCT06604351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, Nab-Paclitaxel, and Carboplatin
Description: Cryoablation received at least 2 or more depending on the mass, with 2-3 cycles；Sintilimab 200 mg Q3W plus Nab-Paclitaxel 260mg / m2(Day 1) Q3W + carboplatin AUC 4.25 or 5 (Day 1) Q3W, 4 cycles，until 24 months
Study NCT06569186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cue-based feedings
Description: Speech therapists will use cue-based protocols to guide feeds
Study NCT06601842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICP monitoring
Description: ICP monitoring
Study NCT06707636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Black Women's Stress and Wellness (B-SWELL) arm
Description: The B-SWELL arm consists of 8-weekly sessions. Sessions last 90 minutes and focus on stress reduction, heart disease, and healthy lifestyle changes. The American Heart Association's Life's Essential 8 metrics are leveraged and culturally tailored in the B-SWELL materials. Participants will also receive personalized health coaching.
Study NCT06707636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Wellness (WE) arm
Description: This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics.